135 related articles for article (PubMed ID: 22695100)
1. Treatments for classic Kaposi sarcoma: a systematic review of the literature.
Régnier-Rosencher E; Guillot B; Dupin N
J Am Acad Dermatol; 2013 Feb; 68(2):313-31. PubMed ID: 22695100
[TBL] [Abstract][Full Text] [Related]
2. Liposomal pegylated doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers.
Kreuter A; Rasokat H; Klouche M; Esser S; Bader A; Gambichler T; Altmeyer P; Brockmeyer NH
Cancer Invest; 2005; 23(8):653-9. PubMed ID: 16377582
[TBL] [Abstract][Full Text] [Related]
3. Disseminated classic Kaposi's sarcoma. Two cases with excellent response to pegylated liposomal doxorubicin.
Castiñeiras I; Almagro M; Rodríguez-Lozano J; Fernández-Jorge B; Paradela S; Pozo JD; Fonseca E
J Dermatolog Treat; 2006; 17(6):377-80. PubMed ID: 17853313
[TBL] [Abstract][Full Text] [Related]
4. Low to moderate cumulative doses of pegylated liposomal doxorubicin in the treatment of classic Kaposi sarcoma in elderly patients with comorbidities.
Potouridou I; Korfitis C; Ioannidou D; Polydorou D; Zakopoulou N; Stratigos AJ; Katsambas AD
Br J Dermatol; 2008 Feb; 158(2):431-2. PubMed ID: 18067475
[No Abstract] [Full Text] [Related]
5. Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: a retrospective study.
Di Lorenzo G; Di Trolio R; Montesarchio V; Palmieri G; Nappa P; Delfino M; De Placido S; Dezube BJ
Cancer; 2008 Mar; 112(5):1147-52. PubMed ID: 18098221
[TBL] [Abstract][Full Text] [Related]
6. Intralesional vincristine as first-line therapy for nodular lesions in classic Kaposi sarcoma: a prospective study in 151 patients.
Brambilla L; Bellinvia M; Tourlaki A; Scoppio B; Gaiani F; Boneschi V
Br J Dermatol; 2010 Apr; 162(4):854-9. PubMed ID: 19995366
[TBL] [Abstract][Full Text] [Related]
7. Total resolution of ocular Kaposi sarcoma with different treatment approaches - a case series and review of literature.
Yeak J; Iqbal T; Zahari M; Ismail F
Int J STD AIDS; 2019 Jul; 30(8):802-809. PubMed ID: 31046617
[No Abstract] [Full Text] [Related]
8. Disseminated classic Kaposi sarcoma in a seven-year-old girl.
Gambichler T; Brown V; Siebold A; Stücker M; Bakirtzi M
Eur J Dermatol; 2021 Apr; 31(2):269-270. PubMed ID: 34001480
[No Abstract] [Full Text] [Related]
9. Efficacy of chemotherapeutics in classic and non-classic Kaposi sarcoma: A single-center retrospective real-world data.
Oyucu Orhan S; Bilgehan Sahin A; Cubukcu E; Deligonul A; Ocak B; Orhan B; Evrensel T
Bosn J Basic Med Sci; 2021 Dec; 21(6):746-751. PubMed ID: 33596402
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy for advanced Kaposi sarcoma.
Lanzotti VJ; Campos LT; Sinkovics JG; Samuels ML
Arch Dermatol; 1975 Oct; 111(10):1331-3. PubMed ID: 53034
[TBL] [Abstract][Full Text] [Related]
11. Intralesional vinblastine injections for treatment of classic Kaposi sarcoma in diabetic patients.
Vassallo C; Carugno A; Derlino F; Ciocca O; Brazzelli V; Borroni G
Cutis; 2015 May; 95(5):E28-34. PubMed ID: 26057517
[TBL] [Abstract][Full Text] [Related]
12. Rapidly progressive classic Kaposi sarcoma in an adolescent: response to interferon alfa therapy and biological correlates.
Guttman-Yassky E; Kra-Oz Z; Cohen A; Sattinger Y; Rot T; Sarid R; Bergman R
Br J Dermatol; 2006 Mar; 154(3):555-7. PubMed ID: 16445793
[No Abstract] [Full Text] [Related]
13. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.
Northfelt DW; Dezube BJ; Thommes JA; Miller BJ; Fischl MA; Friedman-Kien A; Kaplan LD; Du Mond C; Mamelok RD; Henry DH
J Clin Oncol; 1998 Jul; 16(7):2445-51. PubMed ID: 9667262
[TBL] [Abstract][Full Text] [Related]
14. Necrotizing leg gangrene from invasive cutaneous Kaposi sarcoma, reversed by pegylated liposomal doxorubicin.
Goff CB; Stapleton A; Aboulafia DM; Dasanu CA
J Oncol Pharm Pract; 2022 Jun; 28(4):1003-1008. PubMed ID: 35037777
[TBL] [Abstract][Full Text] [Related]
15. Classic Kaposi sarcoma presenting as rapidly growing nodules.
Lim TW; Lee MH; Park JG; Cho BK
Cutis; 2001 Jul; 68(1):50-2. PubMed ID: 11480148
[TBL] [Abstract][Full Text] [Related]
16. Role of pegylated lyposomal doxorubicin (PLD) in systemic Kaposi's sarcoma: a systematic review.
Di Trolio R; Di Lorenzo G; Delfino M; De Placido S
Int J Immunopathol Pharmacol; 2006; 19(2):253-63. PubMed ID: 16831292
[TBL] [Abstract][Full Text] [Related]
17. Peginterferon alfa-2a for AIDS-associated Kaposi sarcoma: experience with 10 patients.
Rokx C; van der Ende ME; Verbon A; Rijnders BJ
Clin Infect Dis; 2013 Nov; 57(10):1497-9. PubMed ID: 23912848
[TBL] [Abstract][Full Text] [Related]
18. Treatment with taxanes of refractory or life-threatening Kaposi sarcoma not associated with human immunodeficiency virus infection.
Fardet L; Stoebner PE; Bachelez H; Descamps V; Kerob D; Meunier L; Dandurand M; Morel P; Lebbe C
Cancer; 2006 Apr; 106(8):1785-9. PubMed ID: 16534786
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma.
Cooley T; Henry D; Tonda M; Sun S; O'Connell M; Rackoff W
Oncologist; 2007 Jan; 12(1):114-23. PubMed ID: 17227906
[TBL] [Abstract][Full Text] [Related]
20. Classic Kaposi's sarcoma: low-dose interferon alfa treatment.
Tur E; Brenner S
Dermatology; 1998; 197(1):37-42. PubMed ID: 9693183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
